Unlocking the potential of antibody-drug conjugates in cervical cancer: emerging targets and clinical trials
Despite significant advances in immune checkpoint inhibitors and targeted therapies, treatment options remain limited for recurrent and metastatic cervical cancer (r/mCC) following progression on first-line therapy. There persists a substantial unmet clinical need for novel therapeutic strategies th...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1636120/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|